ZZ BIOTECH NEWS
ZZ BIOTECH PRESS ROOM
Welcome to our Online Press Room
At ZZ Biotech, not only are we known for providing rich content and value information to our audiences, we are also known for providing easy answers for the news media.
If you’re a member of the news media and working on deadline where we can assist you, please contact our media relations representative via email. We will respond to all media requests within a 24-hour period.
Listed below in chronological order are our news announcements. If you require further assistance with obtaining information contained in one of the announcements, please call our media contact.
ZZ Biotech’s Stroke Drug Moves Closer to Pivotal Phase 3 Clinical Trial as the NIH Awards First Tranche of $30 Million Grant to the Keck School of Medicine of USC
3K3A-APC Granted Fast-Track Designation by FDA with Multinational Clinical Trial to Run Through NIH StrokeNet Houston, May 24, 2022, — In a significant development for
ZZ Biotech Announces First Patients Dosed in Phase 2 Clinical Trial of 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Houston, TX December 2, 2021 — ZZ Biotech, a clinical stage biopharmaceutical company developing the experimental drug 3K3A-APC for some of the biggest unmet needs
HOUSTON, June 12, 2020—ZZ Biotech today announced that the US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC
HOUSTON, January 26, 2018—ZZ Biotech today announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented
A human protein combined with stem cell therapy has been found to repair stroke damage to the brain, according to a new USC-led study on
ZZ Biotech’s regenerative bio drugs manufactured in Brisbane with support of Biopharmaceuticals Australia
ZZ Biotech was awarded a $250,000 grant by BPA to support clinical development of its lead drug product, 3K3A-APC. The drug was manufactured at Patheon’s
Award to Cedars-Sinai Stroke Intervention Researchers Supports Collaborative Study Involving National Institute of Neurological Disorders and Stroke LOS ANGELES (April 22, 2014) – Cedars-Sinai stroke
ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures HOUSTON, April 22, 2014—ZZ Biotech today